DOCK2 and B-cell chronic lymphocytic leukemia: We found that reducing expression of DOCK2 using specific siRNA in primary CLL cells (Fig. 3a, upper panel) impaired the capacity of Wnt5a to induce activation of ERK1/2 (Fig. 3a, middle panels), but not AKT in CLL cells (Fig. 3a, lower panel).